Percentage | 51 | 49 | 70* | 30 |
Age (years) | 66.2 (7.9) | 64.2 (9.7) | 67.5 (7.8) | 67 (10.2) |
Men (%) | 58.06 | 60 | 62.5 | 23.53 |
Disease duration (years) | 8 (4.5) | 6 (4.1) | 6.2 (3.2) | 4.7 (3.6) |
Hoehn and Yahr score | 2.34 (0.83) | 1.98 (0.65) | 3.32 (1.38) | 3.03 (1.34) |
UPDRS-III score | 31.13 (13.11) | 29.18 (13.87) | 50.33 (19.64) | 43.29 (17.17) |
Schwab and England score | 70.32 (22.13) | 75.67 (15.69) | 40.51 (24.7) | 44.12 (26.71) |
MMSE score | 27.26 (2.64) | 27.7 (2.07) | 25.78 (3.79) | 26.53 (2.89) |
Autonomic failure (%) | 41.94 | 27.59 | 95 | 82.35 |
CES-D score | 14.04 (10.37) | 11.9 (10.59) | 21.06 (11.39) | 18.71 (9.1) |
Antidepressant use (%) | 35.48 | 17.24 | 42.5 | 52.94 |
Daily levodopa (mg) | 626.61 (367.24) | 512.5 (349.82) | 565.63 (471.48) | 484.56 (434.22) |
Duration of levodopa therapy (years) | 6.8 (4.01)** | 3.99 (3.49) | 4 (3.66) | 2.71 (3.34) |
Dopamine agonist use (%) | 74.2** | 37.8 | 32.5* | 47.1 |
Amantadine use (%) | 12.9 | 17.24 | 11.8 | 27.5 |